ArticleHuman cell2026
miR-16-2-3p enhances glucocorticoid sensitivity in ulcerative colitis by targeting CREB1 and NF-κB1.
Article in Human cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
In this study, we systematically investigated the role of miR-16-2-3p, a microRNA passenger strand derived from the MIR16-2 hairpin, in glucocorticoid resistance (GCR) and its underlying regulatory mechanisms. The results showed that miR-16-2-3p expression was significantly downregulated in patients with GCR and in glucocorticoid-resistant-like inflammatory models, and was positively correlated with glucocorticoid receptor (GR) expression, accompanied by a reduced responsiveness to the glucocorticoid dexamethasone (Dex). Functional experiments demonstrated that overexpression of miR-16-2-3p enhanced the inhibitory effects of Dex on inflammatory cytokines (interleukin [IL]-1β, IL-6, IL-8, and tumour necrosis factor alpha [TNF-α]) and promoted nuclear translocation of the GR, whereas inhibition of miR-16-2-3p expression attenuated the anti-inflammatory effects of Dex. Mechanistically, cAMP response element-binding protein 1 (CREB1) was identified as a direct target of miR-16-2-3p, and CREB1 silencing promoted GR nuclear translocation and enhanced the anti-inflammatory efficacy of Dex. In addition, miR-16-2-3p further suppressed nuclear factor kappa-B (NF-κB) signalling by targeting NF-κB1 (p105), thereby synergistically strengthening the inhibitory effect of Dex on NF-κB. In vivo, overexpression of miR-16-2-3p significantly improved the pathological phenotype of dextran sulphate sodium (DSS)-induced ulcerative colitis (UC) in mice and enhanced the therapeutic effect of Dex. Our findings revealed a dual molecular mechanism by which miR-16-2-3p enhances glucocorticoid sensitivity (GCS) through targeting CREB1 and NF-κB1, providing experimental evidence for its potential as a novel therapeutic agent for GCR.
Indexed as
Identifiers
42201570What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.